SRTA — Strata Critical Medical, Inc.

Summary of SRTA Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 60.7% year-over-year to $72.5 million, driven by organic growth and acquisitions.
• Clinical Revenue: Rose 22.6% sequentially to $24.3 million; organic growth (excluding acquisitions) was 15.1%.
• Logistics Revenue: Grew 6.9% year-over-year but only 1% sequentially, below expectations.
• Gross Margins: Clinical gross margin improved to 26.1%, while Logistics gross margin fell to 18.4%.
• Operating Cash Flow: Generated $5.7 million; free cash flow was $2.9 million.
• Adjusted EBITDA: Increased to $7.9 million, with a margin of 10.9%.
• Guidance Update: Revenue guidance raised to $285-$295 million; adjusted EBITDA guidance increased to $33-$35 million for 2026.

2. Strategic Updates and Business Highlights

• Acquisitions: Completed three strategic acquisitions in Q2, enhancing clinical services and expanding geographic footprint. Notable acquisitions include:
  • Louisville Perfusion Services and Ohio Valley Perfusion Associates (cardiac surgery support).
  • Heart and Lung Transplant National Recovery Program (surgical organ recovery).
• Capital Deployment: Ahead of schedule with ongoing integration of acquisitions.
• Growth in Clinical Services: Focus on expanding clinical offerings, particularly in Transplant Clinical, which is expected to represent a larger portion of revenue and profit moving forward.

3. Forward Guidance and Outlook

• Q3 Expectations: Anticipate a decline in Logistics revenue by high single digits due to a 3% headwind from a nonexclusive customer and seasonal factors.
• Clinical Growth: Expect approximately 20% sequential growth in Clinical revenue from Q2 to Q3, with continued expansion in the second half of the year.
• Logistics Margin Recovery: Project gross margins in Logistics to improve to 18.5%-20% in the latter half of 2026, with a target of 20% for 2027.
• Free Cash Flow: Expected to be $15-$22 million for 2026, factoring in increased operational costs and working capital needs.

4. Bad News, Challenges, or Points of Concern

• Logistics Performance: Experienced a decline in gross margins and revenue growth due to reduced flying from a key customer and unfavorable customer mix.
• Operational Challenges: Higher-than-expected unscheduled maintenance expenses impacted profitability.
• Market Volatility: Potential risks from fluctuating donor volumes and competition in the transplant logistics market.

5. Notable Q&A Insights

• Market Share in Clinical Services: Management indicated strong sequential growth in Clinical services, suggesting market share gains, particularly in third-party surgical recovery.
• Logistics Margin Restoration: Initiatives are in place to improve Logistics margins by eliminating lower-margin operators and optimizing fleet utilization.
• Acquisition Strategy: The success of recent acquisitions is aiding in sourcing new targets, with a focus on expanding clinical capabilities and enhancing service efficiency.

Overall, Strata Critical Medical reported strong growth in its clinical business while facing challenges in its logistics segment. The company remains optimistic about future growth driven by strategic acquisitions and operational improvements.